Background
Birt-Hogg-Dubé (BHD) syndrome is a hereditary hamartoma syndrome that predisposes patients to develop hair follicle tumors, lung cysts, and kidney cancer. Genetic studies of BHD patients have uncovered the causative gene, FLCN, but its function is incompletely understood.
Methods
Mice with conditional alleles of FLCN and/or peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A), a transcriptional coactivator that regulates mitochondrial biogenesis, were crossbred with mice harboring either muscle creatine kinase (CKM) -Cre or myogenin (MYOG) -Cre transgenes to knock out FLCN and/or PPARGC1A in muscle, or cadherin 16 (CDH16)-Cre transgenes to knock out FLCN and/or PPARGC1A in kidney. Real-time polymerase chain reaction, immunoblotting, electron microscopy, and metabolic profiling assay were performed to evaluate mitochondrial biogenesis and function in muscle. Immunoblotting, electron microscopy, and histological analysis were used to investigate expression and the pathological role of PPARGC1A in FLCN-deficient kidney. Real-time polymerase chain reaction, oxygen consumption measurement, and flow cytometry were carried out using a FLCN-null kidney cancer cell line. All statistical analyses were two-sided.
Results
Muscle-targeted FLCN knockout mice underwent a pronounced metabolic shift toward oxidative phosphorylation, including increased mitochondrial biogenesis (FLCN f/f vs FLCN f/f /CKM-Cre: % mitochondrial area mean = 7.8% vs 17.8%; difference = 10.0%; 95% confidence interval = 5.7% to 14.3%; P < .001), and the observed increase in mitochondrial biogenesis was PPARGC1A dependent. Reconstitution of FLCN-null kidney cancer cells with wild-type FLCN suppressed mitochondrial metabolism and PPARGC1A expression. Kidney-targeted PPARGC1A inactivation partially rescued the enlarged kidney phenotype and abrogated the hyperplastic cells observed in the FLCNdeficient kidney.
Conclusion
FLCN deficiency and subsequent increased PPARGC1A expression result in increased mitochondrial function and oxidative metabolism as the source of cellular energy, which may give FLCN-null kidney cells a growth advantage and drive hyperplastic transformation.
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Affected individuals with Birt-Hogg-Dubé (BHD) syndrome are at risk for the development of multifocal chromophobe and hybrid oncocytic renal cell carcinomas (1, 2) . The FLCN gene (alias BHD) is a tumor suppressor (3-6), but the mechanism by which FLCN deficiency causes kidney cancer is not completely understood. FLCN encodes folliculin (FLCN), a 64-kDa protein with no known functional or structural domain. FLCN binds to two FLCNinteracting proteins, FNIP1 and FNIP2, both of which interact with 5'-adenosine monophosphate-activated protein kinase (AMPK) (7) (8) (9) , and several studies have shown that loss of FLCN modulates activity of the mammalian target of rapamycin (mTOR) pathway (3, 4, (10) (11) (12) . AMPK is an important energy sensor in cells that negatively regulates mTOR (13, 14) . Although the function of FLCN remains to be determined, its involvement in a FNIP1/ FNIP2/AMPK complex and the modulation of mTOR activity in response to FLCN deficiency suggest that FLCN may play a role in cellular energy and nutrient sensing through interaction with the AMPK-mTOR pathway, a precedent seen with other tumor suppressors involved in cell metabolism (15) (16) (17) (18) (19) .
FLCN has been reported to interact with several other pathways in addition to the FLCN and AMPK-mTOR pathways already highlighted. The Drosophila FLCN homolog is required for germline stem cell maintenance through the JAK/STAT pathway (20) . FLCN-null embryonic stem cells and the FLCN-null cancer cell line UOK257 show loss of transforming growth factor β-dependent signaling (10, 21) . Transcriptional activity of TFE3, a member of the MiTF/TFE family, is enhanced by its nuclear localization in FLCN-null cells (22) . Although these reports indicate that FLCN
FACS Analysis
JC-1 (Biotium, Hayward, CA) and tetramethylrhodamine methyl ester (TMRM) (Invitrogen) were used for membrane potential experiments. For JC-1, cells were stained at 37°C in a 5% carbon dioxide incubator for 15 minutes with JC-1 dye. For TMRM, cells were stained at room temperature for 30 minutes with 20nM TMRM. Cells were trypsinized and resuspended into 10% fetal bovine serum in phosphate-buffered saline (PBS). Stained cells were analyzed with CyAn adenosine diphosphate (Beckman Coulter, Brea, CA), and data analysis was performed with FlowJo 7.6.4 software (FlowJo, Ashland, OR).
Quantitative Real-Time Polymerase Chain Reaction
Total RNA was isolated from the flash frozen white portion of the quadriceps muscle, from cell cultures, and from human kidney specimens (surgically treated at the Urologic Oncology Branch, National Institutes of Health, Bethesda, MD, with written patient permission under National Institutes of Health Institutional Review Board-approved protocol 97-C-0147) using TRIzol reagent (Invitrogen), and total RNA was reverse transcribed to cDNA using a Superscript III reverse transcriptase kit (Invitrogen). Quantitative real-time polymerase chain reaction (PCR) was performed with the 7300 Real-Time PCR System (Applied Biosystems, Foster City, CA) using SYBR Green PCR Master Mix (Fermentas, Glen Burnie, CA). Primer sequences are given in Supplementary Table 1 (available online) . Signal intensity obtained from Real-Time PCR System was described in relative units; each value was normalized using 36B4 for muscle tissue experiments and β-actin for other experiments.
Western Blotting, immunofluorescence Staining, and Antibodies Frozen muscle pieces and kidney samples were homogenized in radioimmunoprecipitation assay buffer [20 mM tris(hydroxymethyl) aminomethane-hydrogen chloride pH 7.5, 150 mM sodium chloride, 1 mM ethylenediaminetetraacetic acid, 1.0% Triton X-100, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate] supplemented with Complete protease inhibitor cocktail and PhosStop phosphatase inhibitor cocktail (Roche, Indianapolis, IN). Immunofluorescence staining of human BHD-associated tumor was done as previously reported (3, 4) . Antibodies used included mouse monoclonal FLCN, which was developed by the Monoclonal Antibody Core at the National Cancer Institute, National Institutes of Health, Bethesda, Maryland (7), at 1:1000 dilution, Myoglobin(FL154) at 1:200 dilution, PPARGC1A (H300, Santa Cruz Biotechnology, Santa Cruz, CA) at 1:200 dilution, COX4 at 1:1000 dilution, Cytochrome c (136F3) at 1:1000 dilution,β-actin (Cell Signaling, Danvers, MA) at 1:1000 dilution, and α-tubulin (Sigma Aldrich, St. Louis, MO) at 1:1000 dilution. Antibodyprotein complexes were detected using SuperSignal West pico chemiluminescent substrate (Pierce Biotechnology, Rockford, IL) or Odyssey imager (LI-COR Biotechnology, Lincoln, NE).
electron Microscopy
Specimens of human BHD-associated kidney cancer and normal kidney were obtained with intraoperative core needle biopsies at the Urologic Oncology Branch, National Institutes of Health, Bethesda, Maryland, with written patient permission under National Institutes of Health Institutional Review Board-approved protocol 97-C-0147, and immediately immersed in 4% formaldehyde/2% glutaraldehyde (Electron Microscopy Sciences, Hartfield, PA)/PBS. For specimens of mouse muscle and kidney, the mice were perfused with 5 units/mL heparin/PBS and 4% formaldehyde/2% glutaraldehyde/PBS using a 27-gauge needle immediately after euthanization. The gastrocnemius muscles or kidneys were removed and immersed in 4% formaldehyde/2% glutaraldehyde/PBS. Small blocks were then cut, osmicated, and dehydrated before embedding. The blocks were sectioned and observed in a Jeol 1200 transmission electron microscope equipped with an XR-100 Charge-coupled device camera (Advanced Microscopy Techniques Corporation, Danvers, MA). Percentage of mitochondrial area was analyzed with Image J (National Institute of Health, Bethesda, MD). One sectional image of muscle was divided into 24 square areas, each of which was 20 µm 2 , and the ratios of mitochondrial area to muscle area of 24 areas were measured and represented as means and 95% confidence intervals (CIs). The perinuclear area was omitted because of the abundance of mitochondria. At least three pairs of independent sections were analyzed, and similar results were obtained. For percentage of mitochondrial area in kidney cells, the ratios of mitochondrial area to cell area were measured in at least 20 cells and represented as means and 95% confidence intervals.
Metabolite Analyses
Metabolite profiling analyses using mass spectrometry platforms of liquid chromatography (LC-MS) and gas chromatography (GC-MS) were carried out in collaboration with Metabolon , and LC − platforms. Signal intensity obtained through LC-MS and GC-MS was normalized to protein concentration determined by Bradford protein assays and described in relative units. Nicotinamide adenine dinucleotide, reduced (NADH) was measured using a nicotinamide adenine dinucleotide/NADH quantitation kit (Biovision, Milpitas, CA).
respiratory capacity of cancer cell line and isolated Mitochondria From Muscle tissue Baseline oxygen consumption ratio of doxycycline-inducible UOK257 cells was measured with the XF96 extracellular flux analyzer (Seahorse Bioscience, North Billerica, MA) using 8.3 g/L Dulbecco's modified Eage medium supplemented with 200 mM glutamine, 100 mM sodium pyruvate, 25 mM D-glucose, 63.3 mM sodium chloride, and phenol red. After monitoring baseline respiration, 1 µM oligomycin and 3 µM carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) were injected into wells of the XF96 cell culture plate. For respiratory capacity measurements of isolated mitochondria from muscle tissues, an XF96 V3 PET plate (Seahorse Bioscience) was coated overnight with 1:15 000 polyethyleneimine solution/assay buffer (137 mM potassium chloride, 2 mM monopotassium phosphate, 2.5 mM magnesium chloride, 20 mM HEPES, 0.5 mM EGTA, 0.2% fatty acid-free BSA). One microgram of mitochondria isolated from entire hind limbs using the standard Nagarse method (25) was attached to the plate bottom at 936 g for 10 minutes. The plate was warmed at 37°C for 10 minutes and transferred to the Seahorse XF96 analyzer. State 3 respiration (maximum adenosine diphosphate-stimulated oxygen consumption ratio; oxygen consumption ratio under sufficient substrate for mitochondrial complex) of complex I was measured immediately after addition of 5 mM glutamate, 5 mM malate, and 0.5 mM adenosine diphosphate, and complex IV-dependent respiration was measured immediately after addition of 0.5 mM tetramethyl phenylenediamine and 3 mM ascorbic acid.
Statistical Analysis
Experimental data are summarized as the mean values with 95% confidence intervals (CIs). Statistical analyses were performed using a two-tailed Student's t test for in vivo data and analysis of variance for in vitro data (SPSS Statistics version 20, IBM, Armonk, NY), and differences were considered to be statistically significant at a value of P less than .05. /CKM-Cre: percentage of mitochondrial area mean = 7.8% vs 17.8%, difference = 10.0%, 95% CI = 5.7% to 14.3%, P < .001) (Figure 1, D) .
To further investigate mitochondrial function in FLCNdeficient muscle, we conducted metabolite profiling analyses using LC-MS and GC-MS. Nutrients for fatty acid β-oxidation (Table 1) To clarify the molecular mechanism by which FLCN deficiency increases mitochondrial biogenesis and enhances oxidative metabolism, we examined the expression of genes, including transcription factors and coactivators, which had been reported to regulate mitochondrial biogenesis or whose gene-manipulated murine models resulted in a phenotype similar to that found in our FLCNdeficient model that included red-colored muscle and increased mitochondrial biogenesis (26) (27) (28) . In our screen, we observed increased PPARGC1A mRNA ( Relative tricarboxylic acid cycle metabolite values for citrate and malate were obtained in metabolite profiling analyses on quadriceps muscle tissues of indicated genotypes. Mean ± 95% confidence interval. Quadriceps, n = 6. Student's t test (two-sided). B) Coenzymes for the electron transport chain were measured in quadriceps muscle tissues of indicated genotypes. Nicotinamide adenine dinucleotide, reduced (NADH) was measured using a commercially available kit, and a relative value of flavin adenine dinucleotide was obtained by metabolite profiling analyses. Mean ± 95% confidence interval. Quadriceps, n = 6. Student's t test (two-sided). C) Respiratory capacity of isolated mitochondria was analyzed in muscle tissues of indicated genotypes. State 3 respiration of complex I-and complex IV-dependent respiration was measured by Seahorse XF96 analyzer using mitochondria isolated from the entire hind limb muscle. Mean ± 95% confidence interval. n = 4. Student's t test (twosided). D) Relative ATP amounts were obtained from metabolite profiling analyses on quadriceps muscle tissues of indicated genotypes. Mean ± 95% confidence interval. Quadriceps, n = 6. Student's t test (two-sided). modulates PPARGC1A expression levels to produce an adequate level of mitochondrial oxidative phosphorylation for cellular energy needs.
PPARGC1A is a key regulator of mitochondrial function, oxidative metabolism, and energy homeostasis in a variety of tissues (29) (30) (31) (32) (33) (34) . Notably, muscle-specific PPARGC1A transgenic mice have been shown to develop red-colored muscle with increased mitochondrial biogenesis (27) , and PPARGC1A-null mice are characterized by decreased mitochondrial biogenesis and an inability to increase ATP levels (32) . Moreover, in vitro bioenergetic analyses have revealed that overexpression of PPARGC1A is associated with an increased membrane potential and respiratory capacity (34) (35) (36) (37) . Phenotypes of our mouse model in which FLCN inactivation is directed to muscle and FLCN-null in vitro systems are consistent with those of PPARGC1A overexpressing cells and these findings led us to crossbreed muscle-specific FLCN knockout mice with muscle-specific PPARGC1A knockout mice to see whether increased mitochondrial biogenesis under FLCN deficiency is caused by upregulated PPARGC1A. Notably, increased mitochondrial biogenesis, which was associated with FLCN deletion in mouse muscle, was completely reversed by crossbreeding that resulted in deletion of PPARGC1A alleles ( Figure 5 , A-C). These data strongly support the concept that upregulation of mitochondrial biogenesis caused by FLCN deficiency is PPARGC1A dependent, underscoring a role for FLCN as a physiological negative regulator of PPARGC1A.
To date, few studies have evaluated the role of PPARGC1A in cancer development; therefore, the contribution of PPARGC1A to tumor progression (38, 39) or inhibition is unclear (40) . In addition to its role in energy homeostasis, PPARGC1A has reported functions that include suppression of reactive oxygen species (41), regulation of angiogenesis (42) , and induction of unfolded protein response that mitigates endoplasmic reticulum stress (43) Figure 5, D and E) . Notably, the increased mRNA of these genes was reversed when both FLCN and PPARGC1A were deleted. These results suggest that FLCN-deficient tissues may have increased angiogenesis and upregulated unfolded protein responses through PPARGC1A. Thus, PPARGC1A may contribute to the development of kidney cancer by enhancing angiogenesis and suppressing endoplasmic reticulum stress during FLCN deficiency.
We previously reported that highly proliferating cystic kidneys in kidney-specific FLCN knockout mice have upregulation of the mTOR and MEK/Erk pathways and that rapamycin treatment statistically significantly reduced the kidney size and extended the lifespan of these mice (3) . mTOR has been found to control mitochondrial biogenesis by modulating the interaction between PPARGC1A and YY1, a transcriptional factor whose motif is highly enriched in the promoter region of oxidative phosphorylation genes (28) . However, although we treated our muscle-specific FLCN knockout mice with rapamycin, rapamycin was more effective in suppressing expression of mitochondrial genes in the control mouse group ( (Figure 5, F) . This suggests that the increased mitochondrial biogenesis in FLCN-deficient muscle might be due to upregulated PPARGC1A itself rather than enhanced interaction of PPARGC1A-YY1 by mTOR. Notably, mTORC1 was not activated in FLCN-deficient muscle (data not shown).
To investigate a potential role of PPARGC1A in the pathogenesis of human BHD-associated kidney cancer, we examined PPARGC1A mRNA and observed high mRNA levels in BHDassociated kidney cancer relative to normal kidney (normal kidney from BHD patients, n = 4 vs BHD-associated kidney cancer, n = 5: mean = 1.02 vs 4.45, difference = 3.44, 95% CI = 2.13 to 4.75, P < .001) (Figure 6, A) . In support of this result, we observed elevated protein levels of PPARGC1A in FLCN-deficient mouse tumors compared with adjacent normal kidney (Figure 6, B) . Additionally, we observed increased COX4 staining ( Figure 6 , C), a downstream target of PPARGC1A, and tumor cells filled with increased numbers of mitochondria in human BHD-associated kidney cancer (Figure 6, D) . These results indicate that upregulated PPARGC1A and subsequent increased numbers of mitochondria may play an important role in the growth of FLCN-null tumor cells. We previously reported that kidney-specific FLCN knockout mice develop highly proliferating cystic kidneys by 3 weeks of age (3). In fact, we observed increased PPARGC1A pro-
/CDH16-Cre: n = 2 each; PPARGC1A mean = 3.17 vs 6.82, difference = 3.65, 95% CI =2.71 to 4.59, P = .004) (Figure 7, A) , and this observation led us to crossbreed kidney-targeted FLCN knockout mice with kidney-targeted PPARGC1A knockout mice. Surprisingly, inactivation of PPARGC1A alleles in this mouse model partially reduced the size of the enlarged kidneys (FLCN
f/f /CDH16-Cre: n = 8 each; mean of kidney to body weight ratio = 13.13% vs 9.40%, difference = 3.73%, 95% CI = 2.44% to 5.02%, P < .001) (Figure 7 , B and C). To clarify the underlying mechanism by which inactivation of PPARGC1A reduced the size of FLCN-deficient kidneys, we examined the histology of FLCN/PPARGC1A doubly inactivated kidneys. Previously, we observed the presence of hyperplastic cells with enlarged eosinophilic, granular cytoplasm in FLCN-deficient kidneys (3). Interestingly, we did not observe any hyperplastic cells in the FLCN/PPARGC1A doubly inactivated kidneys (Figure 7,  D) . Furthermore, by electron microscopy we observed increased numbers of mitochondria in 
Discussion
In this study, we report an important role of FLCN in mitochondrial oxidative metabolism. FLCN-deficient muscle in a mouse model displays a distinctive red color and enhanced mitochondrial oxidative metabolism. PPARGC1A expression was high in FLCN-deficient muscle, and inactivation of PPARGC1A in muscle completely reversed the elevated mitochondrial biogenesis. The UOK257 FLCN-null kidney cancer cell line displayed increased mitochondrial function and an elevated level of PPARGC1A mRNA, which were reversed by reconstitution with wild-type FLCN. Human BHD-associated kidney cancer also displayed an elevated level of PPARGC1A mRNA. Furthermore, inactivation of PPARGC1A in a kidney-targeted FLCN-deficient mouse model partially rescued the highly proliferating cystic kidney phenotype. A partial reduction in the size of FLCN-deficient kidneys and complete disappearance of hyperplastic cells that were observed in the FLCN-deficient kidney model (3) underscore the pathological significance of upregulated PPARGC1A in FLCN-null kidney cells.
Although the details of FLCN function have not been completely elucidated, studies have shown that the FLCN pathway interacts with a number of important metabolic pathways, including the AMPK-mTOR (3,4,10-12), TFE3 (22) , and HIF-VEGF (44) pathways. In the current study, we demonstrate that FLCN plays a role in mitochondrial homeostasis, further supporting prior work implicating FLCN in metabolism.
In FLCN-deficient muscle, we did not observe the activation of mTORC1, whereas we previously observed the activation of mTORC1 in FLCN-deficient kidney models (3, 4) . mTORC1 integrates a variety of environmental cues, including energy, nutrient, and growth factors, and, in addition to these inputs, mTORC1 activity in muscle tissues is affected by exercise (45) . Therefore, our observation that mTORC1 was not activated in FLCN-deficient muscle may be due to the particular organ context. The precise mechanism by which FLCN deficiency dysregulates the mTOR pathway will require further study.
In 2010, Klomp et al. reported increased mRNA expression of PPARGC1A in human BHD-associated kidney tumors (46) . In the current study, we have established PPARGC1A as a key molecule that confers enhanced mitochondrial oxidative metabolism on FLCN-deficient cells. Although aerobic glycolysis (known as the "Warburg effect") is thought to be the dominant metabolic pathway active in cancer cells, Otto Warburg originally developed his theory based on the efficiency of ATP production from one molecule of glucose through mitochondrial oxidative phosphorylation (n = 29-30 ATP) compared with glycolysis (n = 2 ATP) (47, 48) , which is a requirement for proliferating cells to maximize energy production (18) . Our data indicating that upregulation of PPARGC1A in response to FLCN deficiency contributes to hyperplastic cell formation in the FLCN-deficient mouse kidneys strongly support the idea that mitochondria are important organelles that can fuel tumor suppressor-null cells to initiate tumorigenesis or acquire a growth advantage driving tumor progression.
Numerous electron microscopy studies have demonstrated increased numbers of mitochondria in sporadic chromophobe renal cell carcinoma and renal oncocytoma compared with normal kidney (49) (50) (51) , and expression profiling analyses of both sporadic (52) (53) (54) (55) (56) and familial (46) chromophobe renal cell carcinoma and renal oncocytoma revealed the increased expression of mitochondrial genes or transcriptional regulators for mitochondrial components. For many years, these observations have raised questions among researchers about the underlying mechanisms by which mitochondria increase in these types of tumors. On the other hand, genetic studies of sporadic chromophobe renal cell carcinoma and renal oncocytoma have reported the rearrangement of mitochondrial DNA in these types of tumors (57) (58) (59) (60) . Taken together, these findings have led researchers to speculate that increased mitochondrial expression might be a compensatory consequence of impaired mitochondrial function. However, our findings that loss of FLCN enhances ATP production and mitochondrial respiratory function support the concept that the increased number of mitochondria observed in BHD-associated kidney cancer is a primary consequence of upregulated PPARGC1A resulting from FLCN deficiency and that FLCN-null cells augment mitochondrial oxidative metabolism by increasing mitochondrial number. Although it is not know whether the FLCN pathway is dysregulated in sporadic chromophobe renal cell carcinoma and renal oncocytoma, increased numbers of mitochondria in these tumor types would suggest the potential for attenuation of a pathway involving FLCN.
In mouse kidneys in which FLCN and PPARGC1A were both inactivated, we no longer detected the eosinophilic, hypertrophic cells with increased numbers of mitochondria that were observed in the FLCN-deficient mouse kidneys. Therefore, it is possible that the increased expression of PPARGC1A and its target genes leading to excess mitochondrial ATP production under FLCN deficiency may contribute to tumorigenesis and/or tumor progression. However, one obvious limitation of this study is that the kidney-targeted FLCN knockout mice die due to renal failure around 3 weeks of age without progression of the hyperplastic cells to malignancy (3) . To address this limitation, we have recently developed another FLCN knockout mouse model in which one FLCN allele is deleted in the germline. Subsequent loss of heterozygosity of the remaining wild-type FLCN allele in kidney cells leads to development of chromophobe and hybrid oncocytic tumors at 18-24 months of age, thereby mimicking the human BHD-associated renal tumor paradigm (4) . Although this in vivo tumor model of BHD requires a longer time frame, it would be interesting to see the consequence of PPARGC1A inactivation on tumor formation in this heterozygous FLCN knockout mouse model.
In addition to its role in mitochondrial homeostasis, PPARGC1A regulates angiogenesis (42) , neutralizes reactive oxygen species, and induces expression of unfolded protein response proteins that mitigate endoplasmic reticulum stress (43) . Because these functions may be important for cancer cells to grow, the PPARGC1A pathway could be a potential therapeutic target in patients with BHDassociated kidney cancer.
Our findings support a role for tumor suppressor FLCN as a physiologically important negative regulator of PPARGC1A, a key regulator of energy homeostasis, and demonstrate that loss of FLCN leads to increased mitochondrial oxidative metabolism with subsequent energy overproduction. Furthermore, PPARGC1A enhances the development of hyperplastic cells and enlarged cystic kidneys in the kidney-targeted FLCN-null mouse model, suggesting that upregulation of PPARGC1A and subsequent increased mitochondrial oxidative metabolism in FLCN-null kidney cells may contribute to renal tumor initiation and/or progression in BHD syndrome. These findings provide a foundation for the management of BHD patients and the development of targeted therapeutic approaches for patients with BHD-associated kidney cancer. 
